financetom
Business
financetom
/
Business
/
Car parts supplier Forvia forecasts 2025 sales at around previous year level
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Car parts supplier Forvia forecasts 2025 sales at around previous year level
Feb 27, 2025 10:53 PM

Feb 28 (Reuters) - Car parts supplier Forvia

said on Friday it sees sales in 2025 slightly above or slightly

below last year's level, reflecting a downturn in automotive

demand dragging into the new year.

The France-based company said in its annual earnings report

that it sees sales between 26.3 billion euros and 27.5 billion

euros ($27.32 billion and $28.56 billion) in 2025 compared to

the 26.97 billion euros it reported for 2024.

The outlook is based on the estimated worldwide

automotive production of 89.5 million vehicles this year, Forvia

said, and takes into account U.S. tariffs that are already

enforced.

Analysts polled by LSEG were expecting 27.74 billion euros

in sales in 2025.

($1 = 0.9628 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BMO on The Day, Week Ahead in Canada
BMO on The Day, Week Ahead in Canada
Nov 11, 2024
07:56 AM EST, 11/11/2024 (MT Newswires) -- Financial markets have mostly settled down after last week's ride, noted Bank of Montreal (BMO). Canadian stocks were pulled higher by the tide of rising United States equities, up 2.1% to near a record high, but they underperformed on the week, said the bank. That might be indicative of what's coming on the...
ARS Pharmaceuticals Licenses Neffy Nasal Spray to ALK-Abello for Europe, Canada
ARS Pharmaceuticals Licenses Neffy Nasal Spray to ALK-Abello for Europe, Canada
Nov 11, 2024
07:52 AM EST, 11/11/2024 (MT Newswires) -- ARS Pharmaceuticals ( SPRY ) said Monday it has granted ALK-Abello exclusive rights to commercialize neffy nasal spray, its emergency treatment for Type I allergic reactions, in Europe, Canada, and other territories outside the US. Under the licensing agreement, ARS Pharmaceuticals ( SPRY ) said it will receive $145 million upfront and up...
Ryvyl Signs MOU for Repayment of Convertible Note, Redemption of  Preferred Stock
Ryvyl Signs MOU for Repayment of Convertible Note, Redemption of Preferred Stock
Nov 11, 2024
07:51 AM EST, 11/11/2024 (MT Newswires) -- Ryvyl ( RVYL ) said Monday it has signed a non-binding memorandum of understanding for the full repayment and termination of an 8% senior convertible note worth $19.0 million and the redemption of all $53.5 million worth of shares of the company's series B convertible preferred stock. Under the terms of the agreement,...
Altimmune Names Greg Weaver Chief Financial Officer
Altimmune Names Greg Weaver Chief Financial Officer
Nov 11, 2024
07:56 AM EST, 11/11/2024 (MT Newswires) -- Altimmune ( ALT ) said Monday it appointed Greg Weaver as chief financial officer. Weaver joins from CFO of Cognito Therapeutics, where he held a similar role, according to the company statement. Altimmune's ( ALT ) CFO, Richard Eisenstadt, died in June 24. Shares of the company were down 0.6% in recent premarket...
Copyright 2023-2026 - www.financetom.com All Rights Reserved